```html

Westermark Disease (Pulmonary Thromboembolism) – Complete Medical Guide

Overview

Westermark disease is an older eponym for pulmonary thromboembolism (PTE)—the sudden blockage of one or more pulmonary arteries by a blood clot that has traveled from elsewhere in the body, most commonly from the deep veins of the legs (deep‑vein thrombosis, DVT). The term “Westermark sign” is also used to describe a specific radiographic finding (regional oligemia) seen on chest X‑ray, but in clinical practice the condition is referred to as pulmonary embolism (PE).

• Who it affects: Adults of any age, though incidence rises sharply after age 60. Men and women are affected equally.
• Prevalence: In the United States, an estimated 60,000–100,000 deaths per year are attributed to PE, and about 900,000 people develop a first‑time PE annually (CDC, 2022).
• Geographic variation: Incidence is higher in industrialized nations where sedentary lifestyles, obesity, and prolonged travel are common.

Because a PE can rapidly impair gas exchange and strain the right side of the heart, it is a medical emergency when massive or sub‑massive. Early recognition and treatment dramatically improve survival.

Symptoms

The clinical picture of PE is notoriously variable; some patients present with classic triad (dyspnea, chest pain, and cough), while others have only subtle signs. Below is a comprehensive list:

Common Symptoms

• Sudden shortness of breath (dyspnea): Often the first and most intense symptom, worsening with exertion or even at rest.
• Pleural chest pain: Sharp, stabbing pain that may worsen on deep inspiration (pleuritic). Pain is usually localized to one side.
• Cough: May be dry or produce blood‑streaked sputum (hemoptysis) in 5–10% of cases.
• Rapid heart rate (tachycardia): Heart rate >100 beats/min is common.
• Rapid breathing (tachypnea): Respiratory rate >20 breaths/min.

Less Common but Important Symptoms

• Syncope or near‑syncope: Indicates a large embolus compromising cardiac output.
• Leg swelling, pain, or redness: Clues to an underlying DVT, the source of the embolus.
• Fever: Low‑grade (<38°C) may accompany an inflammatory response.
• Feeling of “impending doom” or anxiety: Frequently reported in acute PE.
• Blue‑tinged lips or fingertips (cyanosis): Sign of severe hypoxemia.

Symptoms in Special Populations

• Pregnant women: May experience shortness of breath from normal pregnancy, making PE harder to recognize. Leg pain/swelling is a key clue.
• Elderly: May present with vague fatigue, confusion, or worsening of pre‑existing COPD.
• Children: Rare, usually linked to central venous catheters or congenital heart disease; symptoms mirror adult presentation.

Causes and Risk Factors

PE results from a thrombus (blood clot) that dislodges and travels to the pulmonary arterial tree. The underlying process is often the same as that leading to DVT – Virchow’s triad: stasis of blood flow, endothelial injury, and hypercoagulability.

Major Causes

• Deep‑vein thrombosis (DVT): By far the most common source (≈90%).
• Thrombi from other sites: Upper‑extremity DVT (often catheter‑related), right‑heart thrombus, or paradoxical emboli through a patent foramen ovale.
• In‑situ pulmonary artery thrombosis: Rare, usually in patients with severe pulmonary artery atherosclerosis.

Risk Factors

• Recent surgery or major trauma (especially orthopedic procedures) – immobilization → stasis.
• Prolonged immobilization: long‑haul flights, bed rest, cast immobilization.
• Active cancer and chemotherapy – tumor cells release pro‑coagulant factors.
• Hormonal therapy: oral contraceptives, hormone replacement therapy.
• Pregnancy & postpartum period – increased clotting factors, venous compression by the uterus.
• Obesity (BMI ≥ 30 kg/m²) – venous stasis and inflammation.
• Inherited thrombophilias: Factor V Leiden, prothrombin G20210A mutation, protein C/S deficiency.
• Chronic inflammatory diseases: inflammatory bowel disease, lupus, rheumatoid arthritis.
• Smoking – endothelial injury and hypercoagulability.
• Older age (>60 years) – reduced venous flow and higher comorbidity burden.

Diagnosis

Because symptoms can be nonspecific, clinicians use a stepwise approach combining clinical probability assessment, laboratory testing, and imaging.

1. Clinical Prediction Rules

• Wells Score – stratifies patients into low, intermediate, or high probability of PE.
• Revised Geneva Score – another validated tool that does not require subjective elements.

2. Laboratory Tests

• D‑dimer: A fibrin degradation product. Highly sensitive but not specific. A normal D‑dimer effectively rules out PE in low‑probability patients (Mayo Clinic).
• Arterial blood gas (ABG): May show hypoxemia and respiratory alkalosis.
• Troponin & BNP: Elevated levels suggest right‑ventricular strain and help risk‑stratify for aggressive therapy.

3. Imaging Studies

• Computed Tomographic Pulmonary Angiography (CTPA): First‑line imaging in most centers; visualizes clot burden with >95% sensitivity.
• Ventilation‑Perfusion (V/Q) Scan: Used when CTPA contraindicated (e.g., contrast allergy, severe renal failure). A “high‑probability” V/Q pattern supports diagnosis.
• Compression ultrasonography of the lower limbs: Detects DVT; a positive study can suffice for PE diagnosis in high‑probability patients.
• Echocardiography: Bedside transthoracic echo can reveal right‑ventricular dilation or McConnell’s sign in massive PE.
• Chest X‑ray: Usually normal; may show the Westermark sign (regional oligemia) or Hampton’s hump (wedge‑shaped infarct).

4. Risk Stratification

After confirming PE, patients are classified as:

• Massive (high‑risk): Sustained hypotension (SBP < 90 mm Hg) or shock.
• Sub‑massive (intermediate‑risk): Normal blood pressure but evidence of right‑ventricular dysfunction or myocardial injury.
• Low‑risk: Hemodynamically stable, no RV strain.

Treatment Options

Treatment goals are to prevent clot propagation, dissolve the existing embolus, and reduce recurrence.

1. Anticoagulation – the cornerstone

• Initial (parenteral) agents:
  • Low‑molecular‑weight heparin (LMWH) – enoxaparin 1 mg/kg SC q12h.
  • Unfractionated heparin (UFH) – weight‑based IV infusion; preferred if rapid reversal may be needed.
  • Fondaparinux – synthetic pentasaccharide, subcutaneous injection.
• Long‑term oral agents:
  • Direct oral anticoagulants (DOACs): apixaban, rivaroxaban, edoxaban, dabigatran – no routine INR monitoring.
  • Vitamin K antagonists (warfarin) – target INR 2.0–3.0, requiring regular blood tests.
• Duration: 3 months for provoked PE; 6–12 months or indefinite for unprovoked or recurrent disease, adjusted for bleeding risk.

2. Thrombolytic Therapy

Reserved for massive PE or selected sub‑massive cases with hemodynamic compromise.

• Systemic thrombolysis: Alteplase 100 mg IV over 2 h.
• Catheter‑directed thrombolysis or mechanical thrombectomy: Used when systemic thrombolysis is contraindicated or failed (NEJM, 2020).

3. Surgical Embolectomy

Considered for patients with contraindications to thrombolysis and persistent shock. Requires cardiothoracic surgery expertise.

4. Inferior Vena Cava (IVC) Filter

Implanted when anticoagulation is absolutely contraindicated (e.g., active bleeding). Filters are removable in most modern designs.

5. Supportive Care

• Oxygen supplementation to maintain SpO₂ ≥ 94%.
• Hemodynamic support (fluid resuscitation, vasopressors) for shock.
• Pain control with acetaminophen or low‑dose opioids if needed.

6. Lifestyle & Adjunct Measures

• Graduated ambulation as soon as medically safe.
• Compression stockings for symptomatic DVT.
• Education on medication adherence and signs of bleeding.

Living with Westermark Disease (Pulmonary Thromboembolism)

Even after the acute episode resolves, many patients face long‑term considerations.

Medication Management

• Take anticoagulants exactly as prescribed; set daily reminders.
• For warfarin, maintain a consistent diet low in vitamin K fluctuations.
• Report any signs of bleeding (gums, hematuria, melena) to your provider promptly.

Monitoring

• Regular follow‑up visits: typically at 1 month, 3 months, then every 6–12 months.
• For DOACs, labs are usually unnecessary, but periodic kidney and liver function tests are recommended.
• Consider periodic echocardiography if you had right‑ventricular strain.

Physical Activity

• Begin with short walks; increase duration by 5‑10 minutes each day as tolerated.
• Avoid prolonged immobility (e.g., long car rides) without taking breaks to stretch or walk.
• Coordinate with a physical therapist if you have limited mobility.

Travel & Daily Life

• When flying >4 hours, wear graduated compression stockings and do calf‑muscle pumps every 1–2 hours.
• Stay hydrated; avoid alcohol excess which can increase dehydration risk.
• Inform airlines or event organizers about your anticoagulation therapy if you carry injectable medication.

Emotional Health

Living with the knowledge of a potentially life‑threatening condition can cause anxiety. Seek counseling, join support groups (e.g., the International Society on Thrombosis and Haemostasis patient forums), and practice stress‑reduction techniques like deep breathing or mindfulness.

Prevention

Primary and secondary prevention focus on minimizing clot formation.

General Measures

• Maintain a healthy weight (BMI < 25 kg/m²) and regular aerobic exercise.
• Quit smoking; use nicotine‑replacement or counseling programs.
• Stay hydrated, especially during long trips or hot weather.

Medical Prevention Strategies

• Prophylactic anticoagulation: Low‑dose LMWH or unfractionated heparin during high‑risk hospitalizations, orthopedic surgery, or prolonged immobilization.
• Mechanical prophylaxis: Intermittent pneumatic compression devices or graduated compression stockings for patients with bleeding risk.
• Manage chronic conditions: Optimize control of heart failure, COPD, and diabetes.
• Screen for inherited thrombophilia: Consider testing in patients with unprovoked PE, especially if < 50 years old or with a strong family history.

Complications

If untreated or inadequately treated, PE can lead to serious sequelae:

• Right‑ventricular failure: Persistent pressure overload may cause chronic cor pulmonale.
• Chronic thromboembolic pulmonary hypertension (CTEPH): Occurs in ~2–4% of survivors; characterized by persistent dyspnea, exercise intolerance, and may require pulmonary endarterectomy (CDC).
• Recurrent PE/DVT: Highest risk within the first 6 months after the initial event.
• Bleeding complications: From anticoagulation therapy—gastrointestinal, intracranial, or surgical site bleeding.
• Pulmonary infarction: Small portion of lung tissue may die, causing pleuritic pain and hemoptysis.
• Mortality: Massive PE carries a 30‑day mortality of 25–50% without prompt therapy.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, NEJM, and peer‑reviewed thrombosis guidelines (American College of Chest Physicians, 2021).

```